Abstract
Mechanism of action of chondroitin sulphate
Because CS elicits a key role in the articulation, many research groups have focused on the role of CS on the chondrocytes, the synovial membrane and the subchondral bone. [16] . Activation of NF-B increases FLS proliferation, and changes the phenotype of these cells into highly invasive FLS with great motility and ability to secrete cytokines and MMP-13 [17] . [64] . Furthermore, the anti-psoriatic effect of avarol-3'-thiosalicylate [65] , dimethyl fumarate [66] , curcumin [67] and tacrolimus [68] [78] . There is growing evidence supporting that pro-inflammatory cytokines TNF-␣ and IL-1␤ play a crucial role in the disruption of macrovascular and microvascular circulation both in vivo and in vitro [79] . Moreover, markers of inflammation are highly predictive of cardiovascular events [80] .
Effect of chondroitin sulphate on the chondrocyte

Repeated trauma on an articulation increases the release of cytokines such as interleukin-1␤ (IL-1␤) and tumour necrosis factor-␣ (TNF-␣), cytokines that play a key role in the development of osteoarthritis (OA). In chondrocytes, IL-1␤ activates extracellular signal-regulated kinase 1/2 (Erk1/2) and p38 mitogen-activated protein kinase (p38MAPK), and therefore induces the nuclear translocation of the nuclear factor-B (NF-B) and the activator protein-1 (AP-1). These transcription factors bind to consensus sequences of numerous pro-inflammatory genes, and initiate as well as maintain the inflammatory reaction in chondrocytes [5-7]. As a result, IL-1␤ increases the expression of matrix metalloprotease-3 (MMP-3) [8], MMP-9 [9], MMP-13 [8, 10, 11], phospholipase A2 (PLA2) and cyclooxygenase 2 (COX-2) [11, 12], nitric oxide synthase-2 (NOS2), IL-1␤ and TNF-␣ [13]. Using chondrocytes stimulated by IL-1␤ as experimental model, it was demonstrated that CS diminishes IL-1␤-induced NF-B nuclear translocation and sodium nitroprusside-induced chondrocyte apoptosis. The effects of CS are mediated by inhibition of p38MAPK and Erk1/2 phosphorylation. These data suggest that the anti-inflammatory activity of CS is associated with the reduction of Erk1/2 and p38MAPK phosphorylation and nuclear transactivation of NF-B [14].
Effect of chondroitin sulphate on the synovial membrane
Synovial tissue from patients with early osteoarthritis shows activated fibroblast-like synoviocyte (FLS), macrophages, T lymphocytes and mast cells infiltration [15]. Synovial FLS release IL-1␤, IL-6, IL-8, MMP-1, MMP-2, MMP-3, MMP-13, MMP-14, MMP-16, tissue inhibitor of metalloproteinases-1 (TIMP-1), receptor activator of nuclear factor-kappa B ligand (RANKL), transforming growth factor-␤ (TGF-␤), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)
Inhibition of the IB kinase (IKK) complex impedes the phosphorylation of the inhibitor of B (IB␣) and as a consequence, prevents NF-B activation. In synovial macrophages, inhibition of IKK diminishes IL-1␤-induced production of IL-6; moreover, in rats with adjuvant-induced arthritis, intra-articular injection of a specific IKK-␤ inhibitor reduces arthritis activity and bone destruction; synovial inflammation is also decreased as docu-
. The key role of NF-B in inflammatory responses and immune homeostasis is the basis for the search of compounds targeting any step leading to the nuclear translocation of NF-B to treat diseases with an inflammatory component. The beneficial effects of CS for the treatment of OA raise the hypothesis that CS might be effective in other chronic inflammatory processes or diseases because of an autoimmune response. However, in order to accept the hypothesis that CS has a beneficial effect in diseases other than OA, the following question must be answered: can CS inhibition of NF-B nuclear translocation occur in tissues other than the articulation? There is preliminary in vivo evidence supporting an effect of CS on hepatic NF-B nuclear translocation and nitric oxide concentrations; administration of CS (20 mg/kg/day) for 20 and 30 days did not affect NF-B nuclear translocation in healthy rabbits. However, CS prevented the increase of NF-B nuclear translocation and in nitric oxide hepatic concentrations triggered by a turpentine-induced inflammatory [54]. These results confirm in vivo that CS prevents NF-B activation induced by an inflammatory reaction in tissues other than the articulation. The fact that CS modulates NF-B in several tissues, such as chondrocytes, synovial membrane and liver, supports the hypothesis that CS could be of benefit in the treatment of other diseases with an inflammatory or autoimmune component.
Chondroitin sulphate in psoriasis
Keeping in mind the role of inflammation on vascular dysfunction, how CS might exert a beneficial effect on the progression of atherosclerosis and cardiovascular pathology? In first place, there is strong evidence that NF-B is a pivotal transcription factor in the heart and cardiovascular system [81, 82] [71] [72] [73] [74] [75] [76] 
by diminishing NF-B nuclear translocation [14] and by increasing the ratio of OPG/RANKL [29].
A recent study [86] 
examined the effect of CS on vascular injury and on markers of systemic inflammation in a rabbit model of atherosclerosis aggravated by systemic inflammation provoked by chronic antigen-induced arthritis [87]. Administration of CS prophylactically reduced serum concentrations of C-reactive protein and IL-6. Likewise, CS inhibited the expression of chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) and COX-2, and reduced the nuclear translocation of NF-B in peripheral blood mononuclear cells. In femoral lesions, CS diminished the expression of CCL2 and COX-2, as well as the ratio of the intima/media thickness. Moreover, CS reduced the percentage of rabbits that developed vascular lesions in the aorta. These results support that CS may prevent/limit the progression of atherosclerosis, probably by diminishing local and systemic inflammatory reactions.
Recently, the possibility was raised that therapies targeting chronic low-grade inflammation may provide novel future strategies for cardiovascular disease prevention [88] . The [91, 92] . [96] .
Chondroitin sulphate in IBD
IBD, ulcerative colitis (UC) and Crohn's disease (CD), are chronic, relapsing gastro-intestinal disorders (GI) disorders of unknown aetiology. IBD is caused by the hyper-activation of effector immune cells through toll-like receptors (TLRs), primarily in macrophages, which produce high levels of pro-inflammatory cytokines TNF-␣, IL-1␣, IL-6 and IFN, resulting in colonic tissue damage [89]. NF-B activation is markedly induced in IBD patients and through its ability to promote the expression of various pro-inflammatory genes, NF-B strongly influences the course of mucosal inflammation [90]. Moreover, the NF-B-dependent cytokines TNF-␣ and IL-1␣ are essential to the inflammatory reaction in UC and CD
Keeping in mind that IBD results from the activation of TLRs and NF-B, and excessive production of TNF-␣ and IL-1␤, treatment of IBD at each one of these levels has been proposed. To date, there is no effective tool to block directly TLRs [93], but there is preliminary evidence that the activation of the peroxisome proliferator-activated receptor-␥ (PPAR␥), a natural TLRs suppressor and antagonist, by thiazolidenedione ligands, for example troglitazone, pioglitazone and rosiglitazone, reduces colonic inflammation [94]. The murine dextran sulphate sodium-induced colitis (DSS-IC) is significantly attenuated by pioglitazone and netoglitazone, both prophylactically and therapeutically [95]. A recent multi-centre, randomized, double-blind, placebo-controlled clinical trial compared the efficacy of rosiglitazone with placebo for 12 weeks in 105 patients with mild to moderately active UC; after 12 weeks of therapy, 23 patients (44%) treated with rosiglitazone and 12 patients (23%) treated with placebo achieved clinical response; remission was achieved in nine patients (17%) treated with rosiglitazone and one patient (2%) treated with placebo, and moreover, quality of life was improved in patients receiving rosiglitazone. The authors concluded that rosiglitazone was effective in the treatment of mild to moderately active UC
There [99] . [100] . Based on the evidence brought by studies in animals using genetic approaches to inhibit NF-B activity, it was proposed that blocking NF-B might offer particular promise to treat IBD [101] . A recent Cochrane review concluded that TNF-␣ blocking agents, infliximab, CDP571, adalimumab and certolizumab, were effective for the maintenance of remission in patients with CD who have responded to induction therapy [102] . Moreover, current data suggest that infliximab is an effective treatment for patients with moderate-to-severe UC with an inadequate response to conventional glucocorticoid treatment [103] . [107] . [110] .
is evidence that in intestinal biopsies from patients with CD, the phosphorylation of NF-B is considerably increased [97], as is the concentration of TNF-␣ and IL-1␤ [98]. Oxymatrine (OMT) and matrine (MT) are quinolizidine alkaloids with anti-inflammatory properties that improve the DSS-IC by reducing serum levels of TNF-␣ and the expression of NF-B in colonic mucosa
Phytosteryl ferulates are hydroxycinnamic acid derivatives that partially prevent the DSS-IC very probably because they inhibit NF-B activation
Is it reasonable to speculate that CS by inhibiting NF-B phosphorylation and TNF-␣ and IL-1␤ release could be beneficial in patients with
The neuropathological hallmarks of Alzheimer's disease include deposits of amyloid-␤ peptide (A␤), formation of A␤ plaques, accumulation of abnormal tau protein filaments in neurofibrillary tangles, extensive neurodegeneration and signs of chronic inflammation. The A␤ peptides activate NF-B, resulting in the up-regulation of pro-inflammatory cytokines TNF-␣ and IL-1␤, NOS-2, and COX-2 [108, 109]. However, there is debate on whether the inflammation contributes to neurotoxic effects or represents a secondary reaction to A␤ deposition. Several, but not all nonsteroideal anti-inflammatory drugs (NSAIDs) reduce A␤ burden in transgenic mouse models of Alzheimer's disease, effect that may be mediated by either inhibition of COX or by a direct effect on ␥-secretase, thereby reducing A␤ generation independently of COX inhibition
Most epidemiological studies suggest that the risk of suffering Alzheimer's disease is reduced in patients treated with NSAIDs [111] 
. However, clinical trials on anti-inflammatory drugs inclu ding prednisone, hydroxychloroquine and the selective COX-2 inhibitors celecoxib and rofecoxib, showed no effects on cognition. The first large-scale clinical trial on both non-selective and COX-2 selective
NSAIDs was also disappointing [112] . A possible explanation is that these drugs might be protective only at the initial stages of the disease, or even before disease initiation, but may not reverse the degenerative process in patients with esta blished pathology. [113] . Clinical trials showed that rosiglitazone improves cognitive functions in apolipoprotein E4 (ApoE4)-negative patients [114] . Actually, there is evidence that reducing local inflammation with PPAR agonists improves the evolution of diseases such as Alzheimer's and Parkinson [115, 116] , confirming that inflammation is a target for treatment. [117] ; CS inhibits post-injury axonal regeneration [118] . The CS growth inhibitory effect is considered to be a major obstacle for regeneration, and explain in part the lack of effective CNS recovery [119] . Interestingly, inhibition of CS synthesis immediately after injury impairs functional motor recovery and increases tissue loss, however, allowing CS synthesis during 48 hrs following injury, with subsequent inhibition, improves recovery by directly activating microglia/macrophages via the CD44 receptor [120] .
The PPARs are a family of nuclear hormone receptors that regulate immune and inflammatory responses, with an anti-inflammatory effect. Thiadiazolidinone derivatives, PPAR␥ agonists, are potent neuroprotector compounds. Thiadiazolidinones inhibit the inflammatory activation of cultured brain astrocytes and microglia by diminishing lipopolysaccharide (LPS)-induced IL-6, TNF-␣, NOS-2 and COX-2 expression. Neuroprotective effects of thiadiazolidinones are completely inhibited by PPARs antagonists
In the CNS, synthesis of matrix CS by macrophages and oligodendrocyte progenitors is strongly up-regulated after a trauma
The ⌬di-6S disaccharide modulates neuronal and microglial activities; in vitro, in neurons, ⌬di-6S promotes neurite outgrowth and protects against neuronal toxicity and axonal collapse via protein kinase C␣ (PKC␣) and proline-rich tyrosine kinase 2 (PYK2) intracellular signalling pathways; in microglia, ⌬di-6S transforms the phenotype of microglia in neuroprotective by means of the activation of Erk1/2 and PYK2. It is noteworthy that in vivo, systemically or locally injected ⌬di-6S protects neurons in mice subjected to glutamate or aggregated ␤-amyloid intoxication [121, 122] . Recent evidence shows that by regulating multiple genes, ⌬di-6S confers to microglia behaviour a phagocytic and anti-inflammatory profile [123] . The ⌬di-6S may be a promising candidate for pharmacological development as a neuroprotective therapy for acute and chronic neurodegenerative disorders [124] .
Glycosaminoglycans bind A␤ and can promote its aggregation [125] [126] .
In human neuroblastoma SH-SY5Y cells subjected to oxidative stress, CS reduces the formation of reactive oxygen species (ROS) induced by both H2O2 (extracellular ROS) and Rot/oligo (intracellular ROS), effects associated with an increased AKT/PI3K
phosphorylation and heme oxygenase-1 expression [127] . These studies are of particular interest, because it is known that antioxidants elicit a small beneficial effect on the evolution of Alzheimer's and Parkinson diseases [67, 128, 129] .
It has been proposed that glaucoma may be considered as a neurodegenerative disease and treated as other neurodegenerative diseases are treated [130] . In vivo, the ⌬di-6S disaccharide protects retinal ganglion cells from death caused by elevated intra ocular pressure in part through its control of microglial activity, for example ⌬di-6S disaccharide activated the microglia through the activation of Erk1/2 and PYK2 but without increasing TNF-␣ secretion [131] .
Following the intravenous administration of 131 [133, 134] . There is compelling evidence that the increase of Th17 by IL-6 plays a pivotal role in the appearance of autoimmunity, closely associated with the release of IL-17 [134, 135] . IL-17 induces the release of IL-1␤ and TNF-␣ from macrophages [136] , by activating Erk1/2, p38MAPK and NF-B [137] .
In actively demyelinating plaques, the RelA, c-Rel and p50 subunits of NF-B are all present in macrophage nuclei in both parenchymal and perivascular areas; RelA is also found in the nuclei of a subset of hypertrophic astrocytes, suggesting that activation of NF-B has a role in the evolution of MS [138] . In active MS lesions, NF-B and JNK are up-regulated in oligodendrocytes located at the edge of active lesions and in microglia/macrophages throughout plaques [139] . There is evidence that NF-B plays a central role in triggering molecular events in T cells responsible for acute relapse of MS [140] .
The most abundant gene transcript present in early active MS lesions is ␣B-crystallin (CRYAB), whereas it is absent in normal brain tissue [141] . CRYAB has anti-apoptotic and neuroprotective functions [142] , and it is the major target of CD4 ϩ T-cell immunity to the myelin sheath from MS brain [143] . [133] , and CS is capable to downregulate Th2 response [145, 146] . Secondly, it has been reported that inhibition of PLA2 and COX-2 delays the onset, prevents the development and reduces the severity of EAE and greatly reduces antigen-induced production of Th1 and Th17-type cytokines associated with autoimmune response [147] ; it is well documented that CS down-regulates PLA2 [132] and COX-2 [148, 149] . Finally, glucosamine, a natural glucose derivative and an essential component of glycoproteins and PG, suppresses acute EAE, diminishing CNS inflammation and demyelination, effect probably associated with the blockade of Th1 response [150] . This review supports the hypothesis that CS might be an agent beneficial for the treatment of MS, and prompts further studies.
Conclusions
Despite the limitations of the in vitro and in vivo animal models because of differences in CS dosages, routes of administration and duration of exposure, this review supports that by inhibiting nuclear translocation of NF-B and subsequent production of proinflammatory cytokines, and COX-2 and PLA2 expression and activity (Fig. 3) , CS might potentially be of interest for the treatment of many inflammatory and autoimmune diseases, besides OA [151, 152] 
